3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
22
Phase 3
15
Phase 1
13
Phase 1/2
7
Phase NA
1
Phase 2/3
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
1
Interventions
Cisplatin
17
Magnetic Resonance Spectroscopy
16
Specimen Handling
13
pembrolizumab
10
Carboplatin
10
Gemcitabine
9
Paclitaxel
8
Radiotherapy
7
Radiation
7
Platinum
7
1,2-diaminocyclohexaneplatinum II citrate
7
Pemetrexed
6
Nivolumab
6
Doxorubicin
6
Surgical Procedures, Operative
5
Radiotherapy, Intensity-Modulated
5
Docetaxel
5
Dexamethasone
5
Biopsy
5
atezolizumab
4
Rituximab
4
Immunoglobulin G
4
Disulfides
4
Bevacizumab
4
Temozolomide
3
Standard of Care
3
Ramucirumab
3
Drug Therapy
3
Cyclophosphamide
3
Cetuximab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Cytarabine
×
30 days
×
Clear all
NCT04217278
2026-05-05
COSI
University of Birmingham
Phase 2/3
Active not recruiting
333 enrolled